Mipomersen
Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan.
Clinical data | |
---|---|
Trade names | Kynamro |
Other names | ISIS 301012 |
AHFS/Drugs.com | Multum Consumer Information |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | ≥90% |
Metabolism | Nucleases |
Elimination half-life | 1–2 months |
Excretion | <4% in urine in 24 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C230H305N67Na19O122P19S19 |
Molar mass | 7594.76 g·mol−1 |
3D model (JSmol) | |
| |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.